Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.
|Title of host publication||Cancer Immunotherapy|
|Subtitle of host publication||Paradigms, Practice and Promise|
|Publisher||Springer New York|
|Number of pages||20|
|ISBN (Print)||1461447313, 9781461447313|
|State||Published - May 1 2013|